Bioatla Inc (BCAB) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $0.24
• Market Cap: $14.20M
• EPS: $-1.15
• 52-Week High: $1.43
• 52-Week Low: $0.13

Market Sentiment

Bioatla Inc currently has a Neutral sentiment score of 0.10.

About Bioatla Inc

BioAtla, Inc. is a cutting-edge biopharmaceutical firm headquartered in San Diego, California, dedicated to advancing antibody-based therapies for various cancer indications. Leveraging its proprietary Bispecific T cell Engager (BiTEx™) technology, BioAtla is at the forefront of developing innovative treatments designed to selectively target and eradicate cancer cells while preserving healthy tissue. With a strong commitment to addressing critical unmet needs in oncology, the company boasts a...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Bioatla Inc and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does BCAB pay dividends?

Bioatla Inc (BCAB) does not currently pay a regular dividend.

What is BCAB's market cap?

Bioatla Inc (BCAB) has a market capitalization of $14.20M with a current stock price of $0.24.